| Anti-Cancer Compound Library (PP) | Unique collection of anti-cancer compounds under clinical trials | 412 |
| BioActive Lipid Library 2023 (PP) | Includes many compound classes and several complex polyunsaturated fatty acids; ideal for prostanoid or other G protein-coupled receptor screening, target validation, secondary screening, validating new assays, and for routine pharmacological applications. | 1,037 |
| BBB-Permeable CNS Library (PP) | Structurally diverse compounds with properties favorable for BBB-penetration aimed for drug development of CNS-active pharmaceuticals. | 7,100 |
| Cayman Lipid Library | Broad variety of bioactive lipids. | 847 |
| ChemDiv Steroid-like Library (PP) | Steroid-based molecules that regulate biological function | 498 |
| Diversity Set V (LDV) | Selected from the 140K total NCI Developmental Therapeutics Program based on diversity | 1593 |
| Enzo Kinase Inhibitors (LDV) | Known kinase inhibitors of well-defined activity including: Insulin/IFG Receptors, PI 3-Kinase, CaM Kinase II, JAK, PKA,CDK, JNK, PKC, CKI II, MAPK, RAF, EGFR, MEK, SAPK, GSK, MLCK, Src-family, IKK, PDGFR, VEGFR, and more | 80 |
| Epigenetics Library & Epigenetics Library 2019 (PP/LDV) | Variety of structurally and mechanistically different small molecule modulators (inhibitors and activators) with biological activity used for epigenetics research and associated assays. | 171 |
| FDA-Approved Drug Collection | A collection of 978 FDA approved drugs supplied as pre-dissolved DMSO solutions; purchased from SelleckChem. | 1184 |
| Fesik Fragment Library** | This library requires approval from Fesik Lab prior to distribution. | 15,473 |
| GSK Published Kinase Inhibitor Set (LDV) | Small molecule kinase inhibitors spanning over 30 chemotypes that have been previously published by GSK in peer-reviewed scientific journals. | 349 |
| Ion Channel Library (PP) | A collection from Life Chemicals targeted to ion channels compiled using 2D fingerprint similarity methodology. | 6240 |
| Kinase Inhibitor Library (PP) | A unique collection of 429 kinase inhibitors for high-throughput screening and high content screening. | 423 |
| Marnett Library I & II (PP) | NSAID derivatives that contain cyclooxygenase inhibitors, PPARgamma activators, and apoptosis inducers. | 310 |
| Mechanistic Set III (LDV) | Derived from the 37,836 open compounds that have been tested in the NCI human tumor 60 cell line screen. | 813 |
| MLPCN (PP) | MLPCN Screens; requires screening results deposition into PubChem | 16,707 |
| Molecular Libraries Small Molecule Repository (MLSMR)* | Recent acquisition for MLPCN screens; requires screening results deposition into Pubchem. | 76,575 |
| NCI Approved Oncology Drugs Set VI | Contains most current FDA-approved anticancer drugs. The current set (AOD VI) consists of 119 agents and is intended to enable cancer research, drug discovery, and combination drug studies. | 248 |
| NCI Focused Natural Product Collection | Pure compounds acquired by the NCI from Analytical and MerLion. | 936 |
| NIH Clinical Collection I and II (PP) | Small molecules that have history of use in human clinical trials. | 640 |
| Roche (LDV) | Roche (LDV) | 235 |
| SelleckChem FDA (PP) | Unique collection of FDA-approved drugs prior to 2016. | 960 |
| Spectrum Collection 2400 (PP) | Components of the Spectrum Collection selected by medicinal chemists and biologists to provide a wide range of biological activities and structural diversity. | 3,118 |
| Schuppe Collection (PP) | Compounds synthesized by Alex Schuppe and donated to MDSC for screening. | 42 |
| Stork Collection (PP) | Compounds synthesized by Gilbert Stork and donated to MDSC for screening. | 249 |
| Vanderbilt Custom Collection (PP) | Collection of unique chemistry to a range of targets synthesized by Vanderbilt chemists for Vanderbilt investigators. | 2,000 |
| Vanderbilt Discovery Collection (PP) | Selected from Life Chemicals collection for HTS. The compounds in this collection were chosen by Vanderbilt medicinal and computational chemists to provide lead-like motifs, minimum pan-assay interference, and maximum diversity. | 98,880 |
| VICB Collection, Year 4 (LDV) | Diverse set of Drug-like small molecules from Chembridge and ChemDiv. | 148,030 |
| Weaver Library (PP) | Compounds including activators, inhibitors, and dead were made for the GIRK ion channel modulator program. | 294 |
